Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 3 1

Status

Completed 4Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Tumor-Agnostic 2Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 12Neoplasm Metastasis 10Neoplasms 5Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Salivary Gland Neoplasms 1Recurrence 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × trastuzumab deruxtecan × Clear all
NCT07454668 2026-03-06

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Baptist Health South Florida

Phase 1 Not yet recruiting
20 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
292 enrolled 35 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT03383692 2023-12-11

Study of DS-8201a for Participants With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
40 enrolled 20 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Daiichi Sankyo

Phase 1 Completed
12 enrolled 15 charts
BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

NCT03366428 2022-04-12

Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer

Daiichi Sankyo

Phase 1 Completed
51 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡